Determining the Optimal (Neo)Adjuvant Regimen for Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer Regarding Survival Outcome: A Network Meta-Analysis

BACKGROUND: The optimal (neo)adjuvant regimen for human epidermal growth factor receptor-2 (HER2)-positive breast cancer regarding survival outcomes remains unclear. METHODS: We searched Web of Science, PubMed, and the Cochrane Central Register of Controlled Trials systematically to find out randomi...

Descripción completa

Detalles Bibliográficos
Autores principales: Cai, Yu-Wen, Shao, Zhi-Ming, Yu, Ke-Da
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9279606/
https://www.ncbi.nlm.nih.gov/pubmed/35844533
http://dx.doi.org/10.3389/fimmu.2022.919369

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9279606/
https://www.ncbi.nlm.nih.gov/pubmed/35844533
http://dx.doi.org/10.3389/fimmu.2022.919369

Ejemplares similares